MEDICAMEQ vs VINEETLAB: Stock Comparison

Medicamen Biotech Limited vs Vineet Laboratories Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Medicamen Biotech Limited is the larger company by market capitalisation. Medicamen Biotech Limited shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Medicamen Biotech Limited and Vineet Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MEDICAMEQ is more favourable on 10 of 10 scored metrics and VINEETLAB on 0These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MEDICAMEQ is the larger company
₹336 Cr vs ₹73 Cr
EPS
MEDICAMEQ has higher earnings per share
₹7.21 vs ₹-20.47
Dividend Yield
MEDICAMEQ has a higher dividend yield
0.41% vs 0%
Revenue Growth (TTM YoY)
MEDICAMEQ has faster revenue growth
80.2% vs 11.05%
EPS Growth (TTM YoY)
MEDICAMEQ has faster EPS growth
44.7% vs 0%
Qtr Sales Growth
MEDICAMEQ has stronger quarterly sales growth
105% vs -68.8%
Qtr Profit Growth
MEDICAMEQ has stronger quarterly profit growth
59.5% vs 59.2%
ROCE
MEDICAMEQ has a higher ROCE
5.43% vs -28%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMEDICAMEQVINEETLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMEDICAMEQVINEETLAB
Live Price₹247.2₹38.55
Day Change-0.68%5.79%
Volume11,2442.02 L
52-Week High₹447.65₹49.99
52-Week Low₹212.4₹27.96
Distance from 52W High-44.78%-22.88%

Valuation

MetricMEDICAMEQVINEETLAB
Market Cap₹336 Cr₹73 Cr
P/E Ratio32.07x
P/B Ratio1.12x
EPS₹7.21₹-20.47
Book Value₹234.32₹15.84
Dividend Yield0.41%0%

Growth

MetricMEDICAMEQVINEETLAB
Revenue Growth (TTM YoY)80.2%11.05%
EPS Growth (TTM YoY)44.7%0%
Qtr Sales Growth105%-68.8%
Qtr Profit Growth59.5%59.2%

Profitability & Leverage

MetricMEDICAMEQVINEETLAB
ROE3.95%
ROCE5.43%-28%
Net Margin5.21%-26.92%
Operating Margin9.91%-22.4%
Debt to Equity0.17x2.73x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMEDICAMEQVINEETLAB
Promoter Holding40.46%5.98% 6.48 pp
FII Holding0.07% 0.03 pp0.36% 0.36 pp
DII Holding0.4% 0.4 pp
Public Holding59.02% 0.37 pp93.66% 6.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Medicamen Biotech Limited and Vineet Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.